18 May 2024 in The American Journal of Surgery
17 November 2022 in Heliyon
Myoid Hamartoma of the breast (MHB) is an extremely rare benign breast lesion composed of mammary ducts and lobules, fibrous stroma, adipose tissue, and smooth muscle. Due to its rarity, the clinical management of MHB is not well described. Surgical excision is the most common form of management. This study reviews the current literature on the clinical management of MHB and describes a case report of a young patient presenting with MHB managed with surveillance and shared-decision making. A healthy 23-year-old female presented with a one-year history of a palpable left breast mass. Her right breast exam was normal. Ultrasound of the left breast revealed a 2.7 cm × 1.4 cm × 2.4 cm lobulated mass at the one o'clock position. The mass caused slight discomfort to palpation but otherwise had no associated skin changes. Ultrasound-guided biopsy revealed a left breast myoid hamartoma. Management options were presented to the patient, and she elected to observe the mass with surveillance imaging. There have been no reported cases in the literature of malignant transformation of MHB. Rather than rely on reflexive surgical excision of MHB, our review suggests that surveillance and routine imaging may be an appropriate form of clinical management in patients who present with a favorable clinical and histopathological profile which includes: a low MIB-1 proliferative index, low breast cancer risk assessment score, lesion size less than 1.2 cm, and radiological-pathological concordance. Further research is needed to determine the clinical significance and threshold levels of these clinical and histopathological factors in patient care. However, given current trends to minimize over treatment in breast pathology, we pose that observation of MHB can be performed when favorable clinical criteria is met.
22 December 2025 in Journal of Pathology Informatics
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease that can progress to fibrostenotic complications. Lamina propria fibrosis (LPF) plays a critical role in this progression but is difficult to assess reliably in routine biopsies. We aimed to develop and validate an artificial intelligence (AI) model to quantify LPF on hematoxylin and eosin (H&E)-stained slides and to evaluate its ability to predict fibrostenotic disease. We used a cloud-based platform (Aiforia Inc., Cambridge, MA, USA) to train a supervised AI model to recognize several histological features of EoE, including LPF. Our validation cohort consisted of 213 esophageal biopsy whole-slide images, including 100 adult and 113 pediatric samples with mucosal eosinophilia, which were prospectively evaluated in our anatomic pathology service between 2020 and 2021 using a standardized histological scoring system. AI-based LPF scores were correlated with the development of fibrostenotic disease on subsequent endoscopies after a median follow-up time of 31.4 months. The AI fibrosis score correlated with pathologist-determined LPF (Spearman's Rs = 0.64–0.69, p < 0.0001) and outperformed pathologists' assessments in predicting fibrostenotic outcomes. Higher AI fibrosis scores were associated with the development of rings, strictures, and need for dilatation on follow-up (p < 0.01), including in cases deemed histologically inadequate by pathologists and in the subgroup without prior strictures. In a Cox Proportional-Hazards model, the AI fibrosis score was an independent predictor of strictures (C-index = 0.73, p = 0.004). Importantly, meaningful predictions were achievable with smaller amounts of lamina propria than traditionally deemed sufficient. This study demonstrates that AI-based quantification of LPF on routine H&E slides provides an objective and clinically meaningful assessment of fibrosis in EoE. The AI fibrosis score predicts fibrostenotic disease more consistently than conventional pathology evaluation and may improve risk stratification even in limited biopsy samples. Integration of digital pathology tools may enhance histological assessment of fibrosis in EoE and support clinical decision-making.
11 April 2026 in SSRN Electronic Journal
Claudin-18 isoform 2 (CLDN18.2) is a tight junction protein that may become exposed on the tumor cell surface with loss of epithelial polarity, enabling therapeutic targeting. Although CLDN18.2-directed therapies have demonstrated efficacy in gastric and gastroesophageal adenocarcinoma, its expression in lower rectal adenocarcinomas remains poorly defined.Following institutional review board approval (STUDY00025960), we retrospectively evaluated primary rectal adenocarcinomas arising within 2 cm of the dentate line. CLDN18.2 immunohistochemistry was performed, with positivity defined as any tumor cell staining. Clinicopathologic features and outcomes were compared.Among 37 cases, 6 (16.2%) were CLDN18.2-positive. Most clinicopathologic variables were similar between groups. However, CLDN18.2-positive tumors were located significantly closer to the dentate line than CLDN18.2-negative tumors (mean 0.12 cm vs 0.59 cm; p=0.01). CLDN18.2-positive cases also showed higher observed recurrence (83.3% vs 29.0%; p=0.02) and shorter recurrence-free survival on univariate analysis, without a significant difference in overall survival.CLDN18.2 expression is present in a subset of lower rectal adenocarcinomas, particularly in tumors arising near the anorectal junction. These findings suggest possible anatomic and biologic heterogeneity in this setting. While an association with recurrence was observed, this should be interpreted cautiously given the small cohort size. Nevertheless, the identification of CLDN18.2 expression in this subset raises the possibility of biologic relevance with potential implications for future therapeutic stratification.
27 May 2026 in Human Pathology